Jacobson Mark L., COO, reported an open-market or private sale at Axsome Therapeutics, Inc. involving 10000.000000 shares for an estimated $2086500.00. Reported holdings after the transaction were 0.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Operating Officer
Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.
Such transaction was pursuant to a pre-approved 10b5-1 plan.
Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.
0 other filings
0 recent txs